Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain.

Details

Ressource 1Download: 62.pdf (387.45 [Ko])
State: Public
Version: Final published version
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_49D560B90756
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain.
Journal
Intensive care medicine
Author(s)
Bouzat P., Sala N., Suys T., Zerlauth J.B., Marques-Vidal P., Feihl F., Bloch J., Messerer M., Levivier M., Meuli R., Magistretti P.J., Oddo M.
ISSN
1432-1238 (Electronic)
ISSN-L
0342-4642
Publication state
Published
Issued date
03/2014
Peer-reviewed
Oui
Volume
40
Number
3
Pages
412-421
Language
english
Notes
Publication types: Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Experimental evidence suggests that lactate is neuroprotective after acute brain injury; however, data in humans are lacking. We examined whether exogenous lactate supplementation improves cerebral energy metabolism in humans with traumatic brain injury (TBI).
We prospectively studied 15 consecutive patients with severe TBI monitored with cerebral microdialysis (CMD), brain tissue PO2 (PbtO2), and intracranial pressure (ICP). Intervention consisted of a 3-h intravenous infusion of hypertonic sodium lactate (aiming to increase systemic lactate to ca. 5 mmol/L), administered in the early phase following TBI. We examined the effect of sodium lactate on neurochemistry (CMD lactate, pyruvate, glucose, and glutamate), PbtO2, and ICP.
Treatment was started on average 33 ± 16 h after TBI. A mixed-effects multilevel regression model revealed that sodium lactate therapy was associated with a significant increase in CMD concentrations of lactate [coefficient 0.47 mmol/L, 95% confidence interval (CI) 0.31-0.63 mmol/L], pyruvate [13.1 (8.78-17.4) μmol/L], and glucose [0.1 (0.04-0.16) mmol/L; all p < 0.01]. A concomitant reduction of CMD glutamate [-0.95 (-1.94 to 0.06) mmol/L, p = 0.06] and ICP [-0.86 (-1.47 to -0.24) mmHg, p < 0.01] was also observed.
Exogenous supplemental lactate can be utilized aerobically as a preferential energy substrate by the injured human brain, with sparing of cerebral glucose. Increased availability of cerebral extracellular pyruvate and glucose, coupled with a reduction of brain glutamate and ICP, suggests that hypertonic lactate therapy has beneficial cerebral metabolic and hemodynamic effects after TBI.

Keywords
Adult, Brain/drug effects, Brain/metabolism, Brain Injuries, Traumatic/drug therapy, Brain Injuries, Traumatic/metabolism, Energy Metabolism/drug effects, Female, Frontal Lobe/diagnostic imaging, Glucose/metabolism, Humans, Infusions, Intravenous, Lactic Acid/metabolism, Male, Microdialysis/methods, Middle Aged, Neuroprotection, Prospective Studies, Pyruvic Acid/metabolism, Respiration, Artificial, Sodium Lactate/administration & dosage, Sodium Lactate/pharmacology, Time Factors
Pubmed
Web of science
Create date
11/04/2014 17:42
Last modification date
09/09/2021 6:09
Usage data